-
Australia Opens The Door for SKY-0515: Skyhawk Seeks Provisional Approval for Its Oral HD Drug
Latest News
-
The road ahead for uniQure: FDA says more data needed for AMT-130 gene therapy
⏱️ 10 min read | The FDA wants more data before approving AMT-130 for Huntington’s disease in the U.S. On March 2026, uniQure shared in an update that current Phase 1/2 data weren’t enough for the agency. A new randomized, sham-controlled trial may be required.
-
Lighting the way: A new biomarker for Huntington’s disease
A new biomarker reveals brain changes in early Huntington's disease.
-
Novel research technique suggests an antioxidant gene protects vulnerable neurons
Researchers use a new technique in an HD mouse to uncover a gene, Gpx6, that is protective to vulnerable neurons.
-
Building a Better Mouse(trap): A New Model of Huntington’s Disease
New mouse model gives insights into Huntington's disease
-
Taking new targets to the bank: the DNA repair protein ‘ATM’ is overactive in Huntington's disease
HD causes the normally helpful protein "ATM" to get a little overzealous. Now we can look for drugs to settle it down
-
2015 Huntington's Disease Therapeutics Conference: Day 3
Day 3 of updates from the annual HD Therapeutics Conference in Palm Springs
-
2015 Huntington's Disease Therapeutics Conference: Day 2
Day 2 of updates from the annual HD Therapeutics Conference in Palm Springs
-
2015 Huntington's Disease Therapeutics Conference: Day 1
Day 1 of updates from the annual HD Therapeutics Conference in Palm Springs
-
Unlocking the Potential of Antibodies as a Therapy for Huntington’s Disease
Antibodies are known for their role in immunity, but researchers repurpose them in many ways. Can they be used in HD?
-
Drug Improves Huntington’s Symptoms in Mice – and Their Offspring
HD drug changes DNA folding across generations
-
mTORC1 tips the scales in Huntington’s disease mice
Weighing the scales on mTORC1: A possible new target for HD therapeutics?
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
